Integra LifeSciences Holdings (Nasdaq: IART) reported earnings on Feb. 23. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Integra LifeSciences Holdings met expectations on revenues and whiffed on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share shrank significantly.

Margins dropped across the board.

Revenue details
Integra LifeSciences Holdings logged revenue of $203.5 million. The 11 analysts polled by S&P Capital IQ foresaw a top line of $203.1 million on the same basis. GAAP reported sales were 4.8% higher than the prior-year quarter's $194.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.48. The nine earnings estimates compiled by S&P Capital IQ forecast $0.55 per share on the same basis. GAAP EPS of $0.16 for Q4 were 75% lower than the prior-year quarter's $0.63 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 59.3%, 580 basis points worse than the prior-year quarter. Operating margin was 3.8%, 1,540 basis points worse than the prior-year quarter. Net margin was 2.2%, 750 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $195.5 million. On the bottom line, the average EPS estimate is $0.58.

Next year's average estimate for revenue is $837.5 million. The average EPS estimate is $2.66.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 155 members out of 167 rating the stock outperform, and 12 members rating it underperform. Among 64 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 60 give Integra LifeSciences Holdings a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $42.69.

The health-care investing landscape is littered with also-rans and a few major winners. Is Integra LifeSciences Holdings performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.